ARB Starting and Maximum Dosing
For hypertension management, start ARBs at low doses and titrate to maximum doses as tolerated, with specific dosing varying by agent and clinical indication.
Hypertension Dosing
Starting and Maximum Doses for Common ARBs
The following doses are recommended for hypertension treatment [1, 2:
- Losartan: Start 50 mg once daily → Maximum 100 mg once daily (or divided twice daily)
- Valsartan: Start 80 mg once daily → Maximum 320 mg once daily
- Irbesartan: Start 150 mg once daily → Maximum 300 mg once daily
- Candesartan: Start 8 mg once daily → Maximum 32 mg once daily
- Telmisartan: Start 20 mg once daily → Maximum 80 mg once daily
- Olmesartan: Start 20 mg once daily → Maximum 40 mg once daily
- Azilsartan: Start 40 mg once daily → Maximum 80 mg once daily
- Eprosartan: Start 600 mg once daily → Maximum 800 mg once daily (or divided twice daily)
Key Considerations for Hypertension
All ARBs are dosed once daily except losartan and eprosartan, which may require twice-daily dosing for optimal 24-hour blood pressure control [1, 2. The ACC/AHA guidelines classify ARBs as primary agents for hypertension management, with equivalent efficacy to ACE inhibitors, calcium channel blockers, and thiazide diuretics [1, 2.
Avoid combining ARBs with ACE inhibitors or direct renin inhibitors due to increased risk of hyperkalemia, hypotension, and acute kidney injury without additional cardiovascular benefit [1, 2.
Heart Failure with Reduced Ejection Fraction (HFrEF) Dosing
Target Doses for HFrEF
For patients with HFrEF (LVEF ≤40%), ARBs should be titrated to evidence-based target doses shown to reduce mortality and morbidity in clinical trials [3, [3, 3:
- Candesartan: Start 4-8 mg once daily → Target 32 mg once daily
- Losartan: Start 25-50 mg once daily → Target 100 mg once daily (FDA maximum; ACC/AHA recommends 150 mg but this exceeds FDA labeling)
- Valsartan: Start 20-40 mg once daily → Target 160 mg twice daily (320 mg total daily)
- Irbesartan: Target 300 mg once daily
- Telmisartan: Target 80 mg once daily
- Olmesartan: Target 40 mg once daily
- Azilsartan: Target 80 mg once daily
Titration Strategy for HFrEF
Titrate ARB doses every 1-2 weeks as tolerated based on symptoms, vital signs, and laboratory findings (potassium, creatinine) to achieve target doses 4. The 2022 AHA/ACC/HFSA guidelines emphasize that achieving target doses (or maximally tolerated doses) is critical for optimal mortality and morbidity reduction 4.
At minimum, aim for 50% of the target dose if full target doses are not tolerated [3, [3, 3. Studies demonstrate a dose-response relationship, with higher doses providing greater cardiovascular protection [3, [3, 3.
Special Populations
Chronic Kidney Disease (CKD)
For patients with CKD and moderate-to-severe albuminuria (≥30 mg/g), ACE inhibitors are preferred over ARBs for primary prevention based on superior cardiovascular and renal outcomes 5. However, ARBs remain appropriate alternatives when ACE inhibitors are not tolerated 5.
Standard ARB dosing applies for CKD patients, with target SBP <130 mmHg 5. Monitor potassium and creatinine closely, as ARBs increase hyperkalemia risk, especially with GFR <45 mL/min [1, 2.
Combination Therapy
For most hypertensive patients, initiate treatment with a single-pill combination of two agents (typically an ARB or ACE inhibitor plus a calcium channel blocker or thiazide diuretic) at low doses 6. This approach provides faster blood pressure control and improved adherence compared to sequential monotherapy 6.
Never combine an ARB with an ACE inhibitor or direct renin inhibitor—this is potentially harmful and not recommended 2.
Important Safety Considerations
All ARBs carry the following risks [1, [2, 2:
- Hyperkalemia: Especially in CKD, diabetes, or concurrent use of potassium supplements/potassium-sparing diuretics
- Acute kidney injury: Risk increases with bilateral renal artery stenosis
- Angioedema: Rare but serious; if angioedema occurred with an ACE inhibitor, wait 6 weeks before starting an ARB [1, 2
- Pregnancy: Absolutely contraindicated—causes fetal harm and death [1, 2
Monitor serum potassium and creatinine within 1-2 weeks of initiation and after each dose increase [1, 2. A creatinine increase of 0.5-0.7 mg/dL is expected and acceptable 7.